Biotech Values

[Rocky3]

As far as I can tell, there was nothing negative in yesterday’s FY1Q17 financials or CC discussions.

That is true, but GILD's guidance of ongoing market size is very negative, and, if anyone is putting much value in the second generation HCV, those values could easily have changed, maybe dramatically. Of course, that is a reason for a move yesterday, not today. But, past moves would show that the price trend can last a while. I surely am more likely to sell now (same with GILD and Medivir).